Physician profile
Mark H Bowles
NPI 1902884224
$10,518.97
in general payments reported to CMS, 2019-2025
43 companies · $998 in 2025
The $998 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,387 · 2020: $67.51 · 2021: $109 · 2022: $692 · 2023: $459 · 2024: $806 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,179 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,178.96 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,421.49 | 2019 | |
| Abbott Laboratories | $589.10 | 2020-2024 | Jot Dx, Gallant, Cardiomems |
| Janssen Biotech, INC. | $494.77 | 2022-2025 | Tremfya, Stelara, Simponi |
| Sanofi-Aventis U.S. LLC | $308.90 | 2019-2020 | |
| Abiomed | $215.55 | 2022-2025 | Impella |
| Kestra Medical Technology Services, INC. | $201.40 | 2025 | Assure Wcd |
| Shockwave Medical, INC | $186.25 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Acist Medical Systems, INC. | $184.14 | 2019 | |
| Amgen INC. | $176.78 | 2019-2024 | Repatha |
| Sumitomo Pharma America, INC. | $144.66 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $143.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $136.52 | 2019-2025 | |
| Genzyme Corporation | $107.54 | 2024-2025 | |
| Philips North America LLC | $107.17 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $89.18 | 2019 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.